Wiktor Niewiadomski

Dr. Wiktor Niewiadomski

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EPEwelina Pałasz
Ewelina Pałasz
AWAdrianna Wysocka
Adrianna Wysocka
AGAnna Gasiorowska
Anna Gasiorowska
MCMałgorzata Chalimoniuk
Małgorzata Chalimoniuk
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski
GNGrazyna Niewiadomska
Grazyna Niewiadomska
Brain-derived neurotrophic factor (BDNF) promotes neuroprotection and neuroregeneration. In animal models of Parkinson’s disease (PD), BDNF enhances the survival of dopaminergic neurons, improves dopaminergic neurotransmission and motor performance. Pharmacological therapies of PD are symptom-targeting, and their effectiveness decreases with the progression of the disease; therefore, new therapeutical approaches are needed. Since, in both PD patients and animal PD models, decreased level of BDNF was found in the nigrostriatal pathway, it has been hypothesized that BDNF may serve as a therapeutic agent. Direct delivery of exogenous BDNF into the patient’s brain did not relieve the symptoms of disease, nor did attempts to enhance BDNF expression with gene therapy. Physical training was neuroprotective in animal models of PD. This effect is mediated, at least partly, by BDNF. Animal studies revealed that physical activity increases BDNF and tropomyosin receptor kinase B (TrkB) expression, leading to inhibition of neurodegeneration through induction of transcription factors and expression of genes related to neuronal proliferation, survival, and inflammatory response. This review focuses on the evidence that increasing BDNF level due to gene modulation or physical exercise has a neuroprotective effect and could be considered as adjunctive therapy in PD.

6 January 2021 in Life
Verified
Journal Article
Open access
PDF file
GNGrazyna Niewiadomska
Grazyna Niewiadomska
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski
MSMarta Steczkowska
Marta Steczkowska
AGAnna Gasiorowska
Anna Gasiorowska
Although the mechanisms of toxic activity of tau are not fully recognized, it is supposed that the tau toxicity is related rather not to insoluble tau aggregates but to its intermediate forms. It seems that neurofibrillar tangles (NFTs) themselves, despite being composed of toxic tau, are probably neither necessary nor sufficient for tau-induced neuronal dysfunction and toxicity. Tau oligomers (TauOs) formed during the early stages of tau aggregation are the pathological forms that play a key role in eliciting the loss of neurons and behavioral impairments in several neurodegenerative disorders called tauopathies. They can be found in tauopathic diseases, the most common of which is Alzheimer’s disease (AD). Evidence of co-occurrence of b-amyloid, α-synuclein, and tau into their most toxic forms, i.e., oligomers, suggests that these species interact and influence each other’s aggregation in several tauopathies. The mechanism responsible for oligomeric tau neurotoxicity is a subject of intensive investigation. In this review, we summarize the most recent literature on the damaging effect of TauOs on the stability of the genome and the function of the nucleus, energy production and mitochondrial function, cell signaling and synaptic plasticity, the microtubule assembly, neuronal cytoskeleton and axonal transport, and the effectiveness of the protein degradation system.

1 January 2008 in Journal of Human Kinetics
Verified
Journal Article
Open access
PDF file
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski
DLDorota Laskowska
Dorota Laskowska
AGAnna Gąsiorowska
Anna Gąsiorowska
GCGerard Cybulski
Gerard Cybulski
ASAnna Strasz
Anna Strasz
JLJózef Langfort
Józef Langfort
Determination and Prediction of One Repetition Maximum (1RM): Safety Considerations: Strength training is recommended for slowing age-dependent deterioration of muscular strength and for rehabilitating patients with muscle weakening illnesses. Reliable assessment of muscle strength is important for proper design of strength training regimes for prevention, rehabilitation, and sport. One repetition maximum (1RM) is an established measure of muscular strength and is defined as the value of resistance against which a given movement can be performed only once. Proper assessment of 1RM is time consuming, and may lead to muscle soreness as well as temporary deterioration of the function of the tested muscles. Attempts at indirect 1RM determination based on the maximum number of repetitions performed have predicted 1RM with a variable degree of accuracy. Cardiovascular safety has been neglected in 1RM determination, although arterial blood pressure increases considerably when exercising against maximal or near maximal resistance. From the perspective of cardiovascular safety, favorable 1RM measurement methods should avoid performance of repetitions until failure; movement against high resistance and muscle fatigue both increase blood pressure. Although such techniques are likely less accurate than the current methods, their prediction accuracy be sufficient for therapeutic strength training.

1 November 2019 in Frontiers in Neurology
Verified
Journal Article
Open access
EPEwelina Palasz
Ewelina Palasz
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski
AGAnna Gasiorowska
Anna Gasiorowska
AWAdrianna Wysocka
Adrianna Wysocka
ASAnna Stepniewska
Anna Stepniewska
GNGrazyna Niewiadomska
Grazyna Niewiadomska
Parkinson's disease (PD) is manifested by progressive motor, autonomic, and cognitive disturbances. Dopamine (DA) synthesizing neurons in the substantia nigra (SN) degenerate, causing a decline in DA level in the striatum that leads to the characteristic movement disorders. A disease-modifying therapy to arrest PD progression remains unattainable with current pharmacotherapies, most of which cause severe side effects and lose their efficacy with time. For this reason, there is a need to seek new therapies supporting the pharmacological treatment of PD. Motor therapy is recommended for pharmacologically treated PD patients as it alleviates the symptoms. Molecular mechanisms behind the beneficial effects of motor therapy are unknown, nor is it known whether such therapy may be neuroprotective in PD patients. Due to obvious limitations, human studies are unlikely to answer these questions; therefore, the use of animal models of PD seems indispensable. Motor therapy in animal models of PD characterized by the loss of dopaminergic neurons has neuroprotective and neuroregenerative effects, and the completeness of neuronal protection may depend on (i) degree of neuronal loss, (ii) duration and intensity of exercise, and (iii) time elapsed between insult and commencing of training. As the physical activity is neuroprotective for dopaminergic neurons, the question arises what is the mechanism of this protective action. A current hypothesis assumes a central role of neurotrophic factors in the neuroprotection of dopaminergic neurons, even though it is still not clear whether increased DA level in the nigrostriatal axis results from neurogenesis of dopaminergic neurons in the SN, recovery of the phenotype of dopaminergic neurons, increased sprouting of the residual dopaminergic axons in the striatum, or generation of local striatal neurons from inhibitory interneurons. In the present review, we discuss studies describing the influence of physical exercise on the PD-like changes manifested in animal models of the disease and focus our interest on the current state of knowledge on the mechanism of neuroprotection induced by physical activity as a supportive therapy in PD.

20 July 2007 in Clinical Physiology and Functional Imaging
Verified
Journal Article
Closed access
PDF file
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski
AGA. Gąsiorowska
A. Gąsiorowska
BKB. Krauss
B. Krauss
AMAnna Mróz
Anna Mróz
GCGerard Cybulski
Gerard Cybulski

1 September 2004 in Medical & Biological Engineering & Computing
Verified
Journal Article
Closed access
PDF file
GCGerard Cybulski
Gerard Cybulski
EME. Michalak
E. Michalak
EKEdward Kozluk
Edward Kozluk
APA. Piątkowska
A. Piątkowska
Wiktor NiewiadomskiWiktor Niewiadomski
Wiktor Niewiadomski